Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?

Mov Disord. 2022 Aug;37(8):1782. doi: 10.1002/mds.29136.

Matthew Surface¹, Manisha Balwani², Cheryl Waters¹, Alexander Haimovich¹, Ziv Gan-Or^{3

4

5}, Karen S Marder¹, Tammy Hsieh^{6

7}, Linxia Song^{6

7}, Shalini Padmanabhan⁸, Frank Hsieh^{6

7}, Kalpana M Merchant⁸, Roy N Alcalay^{1

9}

¹ Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
² Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Quebec, Canada.
⁴ Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
⁵ Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
⁶ Nextcea, Inc, Woburn, Massachusetts, USA.
⁷ The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
⁸ Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁹ Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

No abstract available

Publication types